3 completed, 1 active not recruiting, 1 recruiting, 1 terminated. 4 Phase 1, 2 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 3, Terminated 1 |
| Phase 2 | 2 | Recruiting 1, Terminated 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Thryv Therapeutics, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of the Efficacy and Safety of THRV-1268 in Participants With Long QT Syndrome Type 2 (LQTS2) and Type 3 (LQTS3) baseline lead-in, THRV-1268 - Long QT Syndrome (LQTS) 2 | Phase 2 / Phase 3 | Recruiting | Thryv Therapeutics, Inc. | 84 | 2026-03-07 | 2026-09-21 |
| Observational Study to Describe Health-Related Quality of Life and Measure Disease Burden Among Patients With Long QT Syndrome Types (LQTS) 2 and 3 Long QT Syndrome Type 3, Long QT Syndrome 2 | Active not recruiting | Thryv Therapeutics, Inc. | 200 | 2025-10-27 | 2026-10-08 | |
| Phase 1, Single Ascending Dose Study to Evaluate the Safety, Tolerability, PK, PD, and Comparative Bioavailability of THRV-1268 in Obese Adult Participants THRV-1268, Placebo - Heart Failure | Phase 1 | Completed | Thryv Therapeutics, Inc. | 16 | 2025-09-15 | 2026-01-14 |
| Study to Assess the Safety, Tolerability, Pharmacokinetic of Thrv-1268 THRV-1268, Placebo - Atrial Fibrillation | Phase 1 | Completed | Thryv Therapeutics, Inc. | 56 | 2024-05-15 | 2025-05-13 |
| Study of LQT-1213 on QTc-induced Prolongation in Healthy Adult Subjects (Part1) and on Congenital Long QT in Patients Diagnosed With Type 2 or 3 Long QT Syndrome (Part 2). LQT-1213, Placebo, Dofetilide 250 μg Cap - Long QT Syndrome | Phase 1 / Phase 2 | Terminated | Thryv Therapeutics, Inc. | 42 | 2023-03-12 | 2025-07-24 |
| Phase 1 Study of LQT-1213 in Healthy Adults LQT-1213, Placebo - Long QT Syndrome | Phase 1 | Completed | Thryv Therapeutics, Inc. | 50 | 2022-09-14 | 2023-09-26 |
Long QT Syndrome (3) · Atrial Fibrillation (2) · Heart Failure (1) · Long QT syndrome type 3 (1) · Long Qt Syndrome 2 (1) · Obesity (1)
Capsules (1) · dofetilide (1)
United States (5) · Canada (1)
Jan Matousek, DO (1)